2026-10-30 15:54:16 UTC#546761duplicateconfirmednews
Sanofi stock news
Sanofi stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-30 12:29:17 UTC#545608duplicateconfirmednews
Regeneron Q3 revenue $5.1B and non-GAAP EPS $20.07, supported by Dupixent and Libtayo growth
quartrimportance 0.30trust 0.70Regeneron Pharmaceuticals, Inc. +0.50Sanofi S.A. +0.40Dupixent +0.40+1 entities
2026-10-30 11:09:18 UTC#544938duplicateconfirmednews
Regeneron Q3 2026 earnings beat expectations on 36% YoY revenue growth
2026-10-30 10:53:00 UTC#544755duplicateconfirmednews
Regeneron Q3 2026 Revenue $5.1B, Non-GAAP EPS $20.07; Announces Sanofi Collaboration and FDA Approval of Pasatru
tradingviewimportance 0.40trust 0.80Regeneron Pharmaceuticals, Inc. +0.60Sanofi S.A. +0.30Pasatru +0.50+1 entities
2026-10-30 10:50:00 UTC#544783duplicateconfirmednews
Sanofi CEO reiterates M&A focus for pipeline growth following FY26 guidance upgrade
2026-10-30 08:18:00 UTC#543817duplicateconfirmedanalysis
J.P. Morgan sees 3-5% consensus forecast upgrades for Sanofi following Q3 earnings beat
dow_jonesimportance 0.30trust 0.80Sanofi S.A. +0.60JPMorgan Chase & Co. +0.20Regeneron Pharmaceuticals, Inc. +0.30+1 entities
2026-10-30 07:54:30 UTC#543723duplicateconfirmednews
Sanofi raises FY26 profit outlook citing strong Dupixent sales
2026-10-30 07:22:00 UTC#543535duplicateconfirmednews
Sanofi raises FY26 outlook on Dupixent strength, signals M&A to address pipeline gaps
dow_jonesimportance 0.30trust 0.80Sanofi S.A. +0.40Regeneron Pharmaceuticals, Inc. +0.30Dupixent +0.40
2026-10-30 06:59:00 UTC#543420updateconfirmednews
Sanofi raises 2026 sales growth outlook, signals intent to pursue M&A
2026-10-30 06:54:00 UTC#543361updatereportednews
Sanofi CEO targets M&A to bolster drug pipeline ahead of Dupixent patent expiration, WSJ reports
2026-10-30 06:47:10 UTC#543305duplicateconfirmednews
Sanofi Q3 earnings beat estimates and FY26 outlook raised
2026-10-30 06:33:08 UTC#543277newconfirmednews
Sanofi Q3 sales up 14.3%, business EPS rises 19.6% on Dupixent strength; FY guidance upgraded
2026-10-29 19:19:00 UTC#540116duplicateconfirmednews
Sanofi Reaches Settlement in Diabetes Treatment Antitrust Litigation
2026-10-29 13:37:00 UTC#537739newconfirmedpress release
Novavax receives $125 million milestone payment as Sanofi initiates Phase 3 flu-COVID combination vaccine trial
2026-10-29 11:30:00 UTC#536818newconfirmedpress release
Sanofi expands Canadian availability of Nuvaxovid protein-based COVID-19 vaccine for 2026-2027 season
2026-10-28 20:45:44 UTC#532493duplicateconfirmednews
Sanofi reaches settlement in US antitrust litigation regarding diabetes drug Lantus
2026-10-28 19:37:30 UTC#532085newconfirmednews
Sanofi settles insulin pen antitrust lawsuit, avoiding trial
2026-10-28 08:03:08 UTC#526893newforecastnews
Sanofi SA Q3 2026 earnings preview: analysts expect $1.51 EPS and $15.277B revenue
2026-10-27 05:00:09 UTC#518712newconfirmedanalysis
Sanofi CEO Belén Garijo faces pressure to bolster drug pipeline as Dupixent revenue growth concerns mount
2026-10-26 09:32:46 UTC#513593newconfirmednews